1 No-Brainer ETF I'm Loading Up on in 2026 and Beyond

The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as a core holding for long-term investors seeking diversified dividend income. With a 3% dividend yield (three times higher than S&P 500 ETFs), low 0.06% expense ratio, and exposure to stable sectors like healthcare and consumer staples, SCHD offers attractive passive income potential. The ETF has delivered 29% total returns year-to-date and is particularly suitable for tax-advantaged accounts like Roth IRAs.

09/08/2026, 2:37 PM • The Motley Fool

Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?

The article compares two healthcare-focused ETFs from iShares: IHE (Pharmaceuticals ETF) with 55 holdings and IYH (Healthcare ETF) with 100 holdings. While IHE delivered stronger 1-year returns of 50% versus IYH's 27.4%, the article recommends IYH as the better choice due to superior 3- and 5-year performance, greater diversification, and larger asset base of $3.9B. Both funds have identical 0.37% expense ratios.

09/08/2026, 2:30 PM • The Motley Fool

Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight

The chronic myeloid leukemia (CML) clinical trial pipeline shows robust activity with 25+ pharmaceutical companies developing 25+ pipeline drugs. Key players including Merck, Enliven Therapeutics, ImmunoForge, and others are advancing promising therapies like TERN-701, ELVN-001, and KF1601 across various clinical stages. The market is evolving from established tyrosine kinase inhibitors toward newer selective agents targeting resistance, intolerance, and treatment-free remission.

09/08/2026, 1:00 PM • GlobeNewswire

Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director

Lindus Therapeutics, a drug development company focused on in-licensed assets, has appointed Dr. Gillian Cannon as a non-executive director. Cannon brings over 30 years of biopharmaceutical commercial leadership experience from roles at Merck and Roivant Sciences. She will help shape the company's commercial strategy as it builds its portfolio of clinical-stage assets.

09/08/2026, 8:00 AM • GlobeNewswire

Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm

Vaxcyte CEO Grant Pickering sold 6,289 shares (~$384,900) to cover tax withholding on vesting restricted stock units, retaining 447,000 direct shares. The clinical-stage biotech company, up 95% over the past year, is awaiting pivotal Phase 3 trial data for VAX-31 in Q4 2026. With $2.5 billion in cash but burning $284.3 million quarterly, the company's future hinges on successful trial results.

09/08/2026, 5:24 AM • The Motley Fool

Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight

The ulcerative colitis market is experiencing significant growth with emerging therapies addressing unmet needs in moderate-to-severe disease. The market, valued at approximately USD 9.4 billion in 2025, is projected to expand at a CAGR of 7.6% through 2036. Five promising late-stage candidates—Obefazimod (Abivax), Tulisokibart (Merck), Afimkibart (Roche), Icotrokinra (J&J/Protagonist), and Duvakitug (Teva/Sanofi)—are reshaping the treatment landscape with novel mechanisms targeting IL-23 and TL1A pathways, while established biologics and oral therapies continue to maintain market presence.

09/07/2026, 1:00 PM • GlobeNewswire

AI in Pharmaceutical Market to Hit USD 48.43 Billion by 2035, Growing at 31.76% CAGR – SNS Insider

The global AI in pharmaceutical market is projected to grow from USD 3.07 billion in 2025 to USD 48.43 billion by 2035, with a CAGR of 31.76%. The U.S. market is expected to reach USD 15.10 billion and Europe USD 12.60 billion by 2035. Growth is driven by generative AI, adaptive trials reducing patient enrollment by 40%, regulatory endorsement including FDA's qualification of AIM-NASH, and increased venture capital investment in AI-first drug discovery platforms.

09/07/2026, 8:30 AM • GlobeNewswire

Where Will SCHD Stock Be in 5 Years?

The Schwab U.S. Dividend Equity ETF (SCHD) has delivered a 57% total return over three years and is recommended as a strong buy for income-focused investors seeking stability and diversification. While the fund offers solid dividend growth (7.53% annually) and exposure to mature, profitable companies, its limited tech exposure (8.2%) means it will miss out on AI-driven gains that boosted the Nasdaq-100 by 92%. The outlook remains positive for the next five years if the U.S. economy continues growing, though trade policy uncertainty and rising bond yields present near-term risks.

09/06/2026, 12:23 PM • The Motley Fool

Schwab U.S. Dividend Equity vs. Vanguard Dividend Appreciation: Which ETF Looks Better for Your Portfolio?

Schwab U.S. Dividend Equity ETF (SCHD) offers nearly double the dividend yield of Vanguard Dividend Appreciation ETF (VIG) at 3% versus 1.5%, with a value-focused portfolio in healthcare and consumer defensives. VIG emphasizes technology stocks and requires 10-year dividend growth streaks. SCHD showed stronger one-year returns (29.5% vs 17.1%) and lower volatility, making it the analyst's preferred choice for income investors seeking higher yields.

09/05/2026, 8:15 AM • The Motley Fool

Want $500 a Month in Passive Income? Start With This Brilliant Dividend ETF.

The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as an effective vehicle for generating sustainable passive income through dividends. With a 3.2% yield and a history of increasing annual dividends since 2011, investors would need approximately $187,500 invested to generate $500 monthly in dividend income. The fund focuses on high-quality dividend-paying stocks and has delivered 13.4% annual returns since inception.

09/04/2026, 5:22 AM • The Motley Fool

BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?

BioNTech and Moderna, both mRNA vaccine pioneers during the pandemic, are now pivoting to cancer vaccines as COVID revenue declines. Moderna is favored due to stronger recent clinical progress, including positive phase 3 results for its personalized cancer vaccine intismeran autogene and FDA approval for mFLUSIVA flu vaccine. While BioNTech has a deep pipeline including pumitamig, it has yet to deliver comparable phase 3 wins. Moderna's $61.2 billion market cap reflects investor confidence in its near-term commercialization prospects versus BioNTech's $26 billion valuation.

09/03/2026, 5:30 PM • The Motley Fool

Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsight

DelveInsight released a comprehensive analysis of the advanced endometrial cancer clinical trial pipeline, identifying 25+ active pharmaceutical companies developing 26+ pipeline drugs. The report highlights emerging therapies including immunotherapies, targeted agents, and antibody-drug conjugates (ADCs) from major players like Pfizer, Genmab, and Incyte Corporation. Recent developments include FDA Fast Track designation for Faeth Therapeutics' PIKTOR combination therapy and positive Phase III results for Merck's sacituzumab tirumotecan, indicating significant momentum in reshaping the advanced endometrial cancer treatment landscape.

09/03/2026, 1:00 PM • GlobeNewswire

Is BioNTech Stock a No-Brainer Buy on the Dip?

BioNTech stock has underperformed significantly, losing 70% over five years as COVID-19 vaccine sales declined. However, the company's mRNA platform is gaining renewed investor interest following Moderna and Merck's successful cancer vaccine trial. BioNTech's diverse pipeline of oncology candidates, including BNT113, BNT116, and pumitamig, could drive future growth, though clinical setbacks remain a risk. The stock appears somewhat attractive but is not a guaranteed buy given its $25.4B valuation and lack of consistent profitability.

09/02/2026, 3:10 PM • The Motley Fool

If the AI Boom Slows Down, History Says This Is the Smartest Way to Protect Your Long-Term Portfolio

As concerns grow about a potential AI market slowdown due to inflation, rate hikes, and geopolitical tensions, investors should consider diversifying into dividend-focused ETFs like SCHD. The Schwab U.S. Dividend Equity ETF offers exposure to 100 stable, dividend-paying stocks across multiple sectors, providing a defensive hedge against AI stock volatility while delivering steady income and historical returns of 243% over the past decade.

09/02/2026, 2:05 PM • The Motley Fool

If I Could Only Buy and Hold 1 Dividend ETF Forever, Here's What I'd Choose

A Motley Fool contributor recommends the Schwab U.S. Dividend Equity ETF (SCHD) as a single buy-and-hold dividend investment. The ETF tracks 100 U.S. stocks with consistent dividend histories and strong fundamentals, features an ultra-low 0.06% expense ratio, and holds well-known companies like Home Depot, Merck, and Procter & Gamble with evenly weighted top holdings to diffuse risk.

09/02/2026, 11:30 AM • The Motley Fool